Share the post "Samrat Pharmachem : Q4 2024 Financial Quarterly Report : YoY Sales Up 19.52 %, QoQ Up 34.06 %"
Highlights
- Sales over the Year and quarter: The company experienced a substantial growth of 19.52 % in the past year, substantial increase in net sales/revenue by 34.06 %.
- Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 1450 %. Marginal decrease of -26.19% in other income during this quarter.
- Profit over the Year and quarter: Challenges in sustaining profitability for Samrat Pharmachem Ltd.. Profit dropped by -287.25 % Year to Year, Samrat Pharmachem Ltd.’s profitability increased by 305.52 % in this quarter.
- EPS over the Year and quarter: EPS declined by -287.55 % Year to Year. EPS increased by 307.21 % in previous quarter. Positive impact on shareholders.
Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
---|---|---|---|---|---|
Sales | Rs. 69.181 Cr | Rs. 61.674 Cr | Rs. 82.683 Cr | + 34.06 % | + 19.52 % |
Expenses | Rs. 69.67 Cr | Rs. 61.56 Cr | Rs. 81.32 Cr | + 32.1 % | + 16.72 % |
Operating Profit | Rs. -0.49 Cr | Rs. 0.11 Cr | Rs. 1.36 Cr | + 1136.36 % | + 377.55 % |
OPM % | -0.71 % | 0.18 % | 1.64 % | + 1.46 % | + 2.35 % |
Other Income | Rs. 0.02 Cr | Rs. 0.42 Cr | Rs. 0.31 Cr | -26.19 % | + 1450 % |
Interest | Rs. 0.17 Cr | Rs. 0.23 Cr | Rs. 0.11 Cr | -52.17 % | -35.29 % |
Depreciation | Rs. 0.16 Cr | Rs. 0.16 Cr | Rs. 0.16 Cr | + 0 % | + 0 % |
Profit before tax | Rs. -0.8 Cr | Rs. 0.14 Cr | Rs. 1.4 Cr | + 900 % | + 275 % |
Tax % | -5.82 % | 143.97 % | 0.43 % | -143.54 % | + 6.25 % |
Net Profit | Rs. -0.75 Cr | Rs. 0.34 Cr | Rs. 1.4 Cr | + 311.76 % | + 286.67 % |
EPS in Rs | Rs. -2.41 | Rs. 1.11 | Rs. 4.52 | + 307.21 % | + 287.55 % |
Today, we’re looking at Samrat Pharmachem Ltd.’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 19.52 %. However, it did see a marginal increase of 34.06 % from the previous quarter. Expenses ticked up slightly by 32.1 % quarter-on-quarter, aligning with the annual rise of 16.72 %. Operating profit, while up 377.55 % compared to last year, faced a quarter-on-quarter increase of 1136.36 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 2.35 %, but an expansion of 1.46 % sequentially. Other income fell by -26.19 % compared to the last quarter, despite an annual growth of 1450 %. Interest expenses dropped significantly by -52.17 % from the previous quarter, yet the year-over-year decrease remains at a moderate -35.29 %. Depreciation costs climbed by 0 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 0 %. Profit before tax grew annually by 275 % but saw an increase from the preceding quarter by 900 %.
Tax expenses as a percentage of profits increased slightly by 6.25 % compared to last year, with a more notable quarter-on-quarter decrease of -143.54 %. Net profit rose by 286.67 % year-on-year but experienced a 311.76 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 287.55 % but a quarterly rise of 307.21 %. In summary, Samrat Pharmachem Ltd.’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
---|---|---|---|---|---|
Sales | Rs. 69.181 Cr | Rs. 61.674 Cr | Rs. 82.683 Cr | + 34.06 % | + 19.52 % |
Expenses | Rs. 69.67 Cr | Rs. 61.56 Cr | Rs. 81.32 Cr | + 32.1 % | + 16.72 % |
Operating Profit | Rs. -0.49 Cr | Rs. 0.11 Cr | Rs. 1.36 Cr | + 1136.36 % | + 377.55 % |
Net Profit | Rs. -0.75 Cr | Rs. 0.34 Cr | Rs. 1.4 Cr | + 311.76 % | + 286.67 % |
EPS in Rs | Rs. -2.41 | Rs. 1.11 | Rs. 4.52 | + 307.21 % | + 287.55 % |
In reviewing Samrat Pharmachem Ltd.’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 19.52 % year-on-year growth, however, there was a minor increase of 34.06 % from the previous quarter. Expenses rose by 16.72 % compared to the previous year, with a 32.1 % increase quarter-on-quarter. Operating Profit surged by 377.55 % annually, and saw a 1136.36 % increase from the last quarter.
Net Profit showed yearly increase of 286.67 %, and experienced a 311.76 % increase from the previous quarter. Earnings Per Share (EPS) rose by 287.55 % annually, however rose by 307.21 % compared to the last quarter. In essence, while Samrat Pharmachem Ltd. exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.